Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 7/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4053518 | 0.98 | GRIN2B (0.56) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL10399460 | 0.86 | MTNR1A (0.51) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL2980045 | 0.86 | GRIN2B (0.47) | GRIN2BCA1CA2SIGMAR1GBA1 | |
| SCHEMBL28583286 | 0.82 | CA1 (0.48) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL24427605 | 0.80 | GRM5 (0.46) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL30479468 | 0.80 | GRIN2B (0.54) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL29033596 | 0.80 | GRIN2B (0.54) | GRIN2BMTNR1AMTNR1BCA1CA2 | |
| SCHEMBL10399768 | 0.80 | TAOK1 (0.55) | GRIN2BSIGMAR1 | |
| SCHEMBL9449692 | 0.79 | GRIN2B (0.50) | GRIN2BMAOAMAOBGBA1 | |
| SCHEMBL11851549 | 0.78 | CA1 (0.57) | GRIN2BMTNR1AMTNR1BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033052-A1 | Dermal anesthetic compounds | WRIGHT GEORGE E | 2008-02-07 | — | — | US | claimed |
| WO-2008011161-A2 | DERMAL ANESTHETIC COMPOUNDS | BRIDGE PHARMA, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| CN-102351712-B | Preparation method of N-phenyl-tetrahydro-2-naphthylamine | JUNKAI TIANJIN CHEMICAL CO LTD | 2013-11-27 | — | — | CN | disclosed |
| CN-102351712-B | Preparation method of N-phenyl-tetrahydro-2-naphthylamine | JUNKAI TIANJIN CHEMICAL CO LTD | 2013-11-27 | — | — | CN | disclosed |
| CN-102351712-A | New preparation method of N-phenyl-tetrahydro-2-naphthylamine | JUNKAI TIANJIN CHEMICAL CO LTD | 2012-02-15 | — | — | CN | disclosed |
| CN-102351712-A | New preparation method of N-phenyl-tetrahydro-2-naphthylamine | JUNKAI TIANJIN CHEMICAL CO LTD | 2012-02-15 | — | — | CN | disclosed |
| US-7592458-B2 | Dermal anesthetic compounds and pharmaceutical compositions for inducing local anesthesia and mitigating neuropathic pain | WRIGHT GEORGE E | 2009-09-22 | — | — | US | disclosed |
| US-7592458-B2 | Dermal anesthetic compounds and pharmaceutical compositions for inducing local anesthesia and mitigating neuropathic pain | WRIGHT GEORGE E | 2009-09-22 | — | — | US | disclosed |
| US-7592458-B2 | Dermal anesthetic compounds and pharmaceutical compositions for inducing local anesthesia and mitigating neuropathic pain | WRIGHT GEORGE E | 2009-09-22 | — | — | US | disclosed |
| US-20080033052-A1 | Dermal anesthetic compounds | WRIGHT GEORGE E | 2008-02-07 | — | — | US | disclosed |
| US-20080033052-A1 | Dermal anesthetic compounds | WRIGHT GEORGE E | 2008-02-07 | — | — | US | disclosed |
| US-20080033052-A1 | Dermal anesthetic compounds | WRIGHT GEORGE E | 2008-02-07 | — | — | US | disclosed |
| WO-2008011161-A2 | DERMAL ANESTHETIC COMPOUNDS | BRIDGE PHARMA, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011161-A2 | DERMAL ANESTHETIC COMPOUNDS | BRIDGE PHARMA, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-3984464-A | ANTIARRHYTHMIA AGENTS | A. CHRISTIAENS SOCIETE ANONYME (BE) | 1976-10-05 | — | — | US | disclosed |
| US-3970650-A | DRUG INTERMEDIATE | A. CHRISTIAENS SOCIETE ANONYME (BE) | 1976-07-20 | — | — | US | disclosed |
| US-3943172-A | ANTIARRHYTHMIA | A. CHRISTIAENS, SOCIETE ANONYME (BE) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033052-A1 | Dermal anesthetic compounds | TRPA1, FABP4, TRPV1 | GRIN2B 2871/4885MTNR1A 1309/4885MTNR1B 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.